

PALM INTRANET

Day : Wednesday

Date: 5/14/2003 Time: 09:29:10

Inventor Name Search Result

Your Search was:

Last Name = KASAMA First Name = TOSHIO

Application#	Patent#	Status	Date Filed	Title	Inventor Name
10009476	Not Issued	030		OPHTHALMIC OINTMENTS FOR TREATMENT INFECTIVE EYE DISEASE	KASAMA, TOSHIO
08460990	5509895	150	06/05/1995	AIR TRAP CHAMBER FOR BLOOD DIALYSIS CIRCUIT CONTAINING AN ANTICOAGULANT COMPOSITION	KASAMA, TOSHIO
<u>08460983</u>	5637081	150	06/05/1995	ANTICOAGULANT COMPOSITION FOR USE IN BLOOD DIALYSIS CIRCUIT	KASAMA , TOSHIO
08167221	5421815	150	12/14/1993	BLOOD DIALYSIS USING ANTICOAGULENT COMPOSITION	KASAMA , TOSHIO
07583860	Not Issued	001	09/17/1990	?	KASAMATSU , TOSHIO
<u>07531698</u>	5357344	250	04/20/1990	METHOD OF AND APPARATUS FOR RECORDING HALFTONE IMAGE	KASAMATSU , TOSHIO
07393271	5093339	150	08/14/1989	PYRANO (F) QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME	KASAMA , TOSHIO
<u>07048814</u>	Not Issued	161	05/12/1987	4-ETHYLAMINO-2-BUTYNYL PHENYL- CYCLOHEXYLGLYCOLATE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF	KASAMA , TOSHIO

Inventor Search Completed: No Records to Display.

Last Name

First Name

Search Another: Inventor kasama toshio Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

Day: Wednesday

Date: 5/14/2003

Time: 09:29:38

PALM INTRANET

Inventor Name Search Result

Your Search was:

Last Name = NOTO

First Name = MITSURU

Application#	Patent#	Status	Date Filed	Title	Inventor Name
10009476	Not Issued	030		OPHTHALMIC OINTMENTS FOR TREATMENT INFECTIVE EYE DISEASE	NOTO, MITSURU

Inventor Search Completed: No Records to Display.

Search Another: Inventor noto First Name Search Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

PALM INTRANET

Day : Wednesday

Date: 5/14/2003 Time: 09:30:21

Inventor Name Search Result

Your Search was:

Last Name = OGURO First Name = SUSUMU

Application#	Patent#	Status	Date Filed	Title	Inventor Name
10009476	Not Issued	030		OPHTHALMIC OINTMENTS FOR TREATMENT INFECTIVE EYE DISEASE	OGURO, SUSUMU

Inventor Search Completed: No Records to Display.

Search Another: Inventor oguro First Name

Search Search Susumu

Search

g

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

Day: Wednesday

PALM INTRANET

Date: 5/14/2003
Time: 09:31:25

Inventor Name Search Result

Your Search was:

Last Name = HANAZOME

First Name = ISAO

Application#	Patent#	Status	Date Filed	Title	Inventor Name
10009476	Not Issued	030		OPHTHALMIC OINTMENTS FOR TREATMENT INFECTIVE EYE DISEASE	HANAZOME, ISAO

Inventor Search Completed: No Records to Display.

Search Another: Inventor hanazome First Name Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

h e eb cg b e f e h

Day: Wednesday

PALM INTRANET

Date: 5/14/2003 Time: 09:32:33

Inventor Name Search Result

Your Search was:

Last Name = TATEKAWA

First Name = RENA

Application#	Patent#	Status	Date Filed	Title	Inventor Name
10009476	Not Issued	030		OPHTHALMIC OINTMENTS FOR TREATMENT INFECTIVE EYE DISEASE	TATEKAWA, RENA

Inventor Search Completed: No Records to Display.

	Last Name	First Name	
Search Another: Inventor			
	tatekawa	rena	Search

To go back use Back button on your browser toolbar.

Back to PALM ASSIGNMENT OASIS Home page

WEST Search History

DATE: Wednesday, May 14, 2003

Set Name side by side	Query	Hit Count	Set Name result set
DB = USPT, PG	PB,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=OR		
L4	L1 and opthalm?	1	L4
L3	L1 and ophthalm?	2	L3
L2	L1 and ophthalm?.	0	L2
L1	(vancomycin hydrochloride)	117872	L1

END OF SEARCH HISTORY

Welcome to STN International! Enter x:x LOGINID: sssptau153cxa PASSWORD: TERMINAL (ENTER 1, 2, 3, OR ?):2 Welcome to STN International NEWS 1 Web Page URLs for STN Seminar Schedule - N. America "Ask CAS" for self-help around the clock NEWS 2 Apr 08 NEWS 3 Jun 03 New e-mail delivery for search results now available NEWS 4 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN NEWS 5 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN NEWS 6 Aug 26 Sequence searching in REGISTRY enhanced NEWS 7 Sep 03 JAPIO has been reloaded and enhanced Sep 16 Experimental properties added to the REGISTRY file NEWS 8 NEWS 9 Sep 16 CA Section Thesaurus available in CAPLUS and CA NEWS 10 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985 NEWS 11 Oct 24 BEILSTEIN adds new search fields NEWS 12 Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN NEWS 13 Nov 18 DKILIT has been renamed APOLLIT NEWS 14 Nov 25 More calculated properties added to REGISTRY NEWS 15 Dec 04 CSA files on STN NEWS 16 Dec 17 PCTFULL now covers WP/PCT Applications from 1978 to date NEWS 17 Dec 17 TOXCENTER enhanced with additional content NEWS 18 Dec 17 Adis Clinical Trials Insight now available on STN NEWS 19 Jan 29 Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC NEWS 20 Feb 13 CANCERLIT is no longer being updated NEWS 21 Feb 24 METADEX enhancements NEWS 22 Feb 24 PCTGEN now available on STN NEWS 23 Feb 24 TEMA now available on STN NEWS 24 Feb 26 NTIS now allows simultaneous left and right truncation NEWS 25 Feb 26 PCTFULL now contains images NEWS 26 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results NEWS 27 Mar 19 APOLLIT offering free connect time in April 2003 NEWS 28 Mar 20 EVENTLINE will be removed from STN NEWS 29 Mar 24 PATDPAFULL now available on STN NEWS 30 Mar 24 Additional information for trade-named substances without structures available in REGISTRY NEWS 31 Apr 11 Display formats in DGENE enhanced NEWS 32 Apr 14 MEDLINE Reload NEWS 33 Apr 17 Polymer searching in REGISTRY enhanced NEWS 34 Apr 21 Indexing from 1947 to 1956 being added to records in CA/CAPLUS NEWS 35 Apr 21 New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX NEWS 36 Apr 28 RDISCLOSURE now available on STN NEWS 37 Pharmacokinetic information and systematic chemical names May 05 added to PHAR NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),

AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003

- 1.10 ANSWER 40 OF 41 MEDLINE
- 87066197 AN MEDLINE
- DN 87066197
- Treatment of experimental methicillin-resistant Staphylococcus epidermidis ΤI endophthalmitis with intravitreal vanc mycin. ΑU
- Smith M A; Sorenson J A; Lowy F D; Shakin J L; Harrison W; Jakobiec F A
- NC 5 T32 AI0718306 (NIAID)
- SO OPHTHALMOLOGY, (1986 Oct) 93 (10) 1328-35.
 - Journal code: OI5. ISSN: 0161-6420.
- CY United States
- DТ Journal; Article; (JOURNAL ARTICLE)
- LA English
- FS Priority Journals
- EM 198703
- Endophthalmitis remains a dreaded complication of intraocular surgery and AB penetrating eye trauma. Subconjunctival, topical, and systemic antibiotics have been largely ineffective in the treatment of endophthalmitis, whereas intravitreal antibiotics have proved efficacious. Methicillin-resistant Staphylococcus epidermidis has become an important pathogen in many infections, including endophthalmitis. Toxicity, clearance, and efficacy of intravitreal vancomycin were evaluated in the treatment of experimental methicillin-resistant S. epidermidis endophthalmitis. No evidence of retinal toxicity was found and therapeutic levels were demonstrated six days after injection. The treated rabbit eyes showed a marked beneficial effect when compared to the untreated eyes. If experience confirms the safety of intravitreal vancomycin in human eyes, vancomycin should be considered the drug of choice for methicillin-resistant S. epidermidis endophthalmitis.

L10 ANSWER 36 OF 41 MEDLINE

AN 92133925 MEDLINE

DN 92133925

TI Methicillin-resistant Staphylococcus aureus corneal ulcers.

AU Eiferman R A; O'Neill K P; Morrison N A

CS Department of Ophthalmology & Visual Science, University of Louisville, Kentucky..

SO ANNALS OF OPHTHALMOLOGY, (1991 Nov) 23 (11) 414-5. Journal code: 5PA. ISSN: 0003-4886.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199205

Three patients with corneal ulcers had gram-positive cocci isolated on initial scrapings. There was no response to topical fortified aminoglycosides or cephalosporins. Cultures revealed methicillin-resistant Staphylococcus aureus that was sensitive only to topical vancomycin eye drops. Because the microbiologic spectrum is similar, vancomycin should be considered instead of a cephalosporin in the treatment of corneal ulcers to cover methicillin-resistant S. aureus and S. epidermidis.

L10 ANSWER 33 OF 41 MEDLINE

AN 92374002 MEDLINE

DN 92374002

TΙ MRSA ocular infections.

ΑU Tazawa H; Ooishi M

CS Department of Ophthalmology, School of Medicine, Niigata University.. NIPPON RINSHO. JAPANESE JOURNAL OF CLINICAL MEDICINE, (1992 May) 50 (5) so

1122-6.

Journal code: KIM. ISSN: 0047-1852.

CY Japan

DΤ Journal; Article; (JOURNAL ARTICLE)

LA Japanese

EM 199211

AR Staphylococcus aureus and Staphylococcus epidermidis are organisms that frequently cause conjunctivitis, keratitis and endophthalmitis. MRSA comprised about 25% of the S. aureus isolated from ocular infections; most were from compromised host. MRSA was resistant to penicillins, cephems and macrolides but was sensitive to amikacin, netilmicin, minocycline and ofloxacin. Ofloxacin-resistant strains, however increased rapidly. Topical vancomycin, arbekacin and minocycline were used when commercially available antibiotics were inadequate.

hiespeistle vancongen salt.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 09:15:48 ON 14 MAY 2003

=> file caplus uspatful japio europatful medline biosis embase

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

SESSION

FULL ESTIMATED COST

0.21
0.21

FILE 'CAPLUS' ENTERED AT 09:16:13 ON 14 MAY 2003 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 09:16:13 ON 14 MAY 2003 CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 09:16:13 ON 14 MAY 2003 COPYRIGHT (C) 2003 Japanese Patent Office (JPO) - JAPIO

FILE 'EUROPATFULL' ENTERED AT 09:16:13 ON 14 MAY 2003 COPYRIGHT (c) 2003 WILA Verlag Muenchen (WILA)

FILE 'MEDLINE' ENTERED AT 09:16:13 ON 14 MAY 2003

FILE 'BIOSIS' ENTERED AT 09:16:13 ON 14 MAY 2003 COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 09:16:13 ON 14 MAY 2003 COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

- => s vancomycin hydrochloride
 - 3 FILES SEARCHED...
 - 4 FILES SEARCHED...
- L1 760 VANCOMYCIN HYDROCHLORIDE
- => s l1 and ophthalm?
 - 4 FILES SEARCHED...
- L2 65 L1 AND OPHTHALM?
- => s 12 and keratitis
 - 4 FILES SEARCHED...
- L3 11 L2 AND KERATITIS

=> s 13 and (paraffin or petrolatum or lanolin or (gelation hydrocrabon) or (polyethylene glycol) or (ointment base)) 4 FILES SEARCHED... 11 L3 AND (PARAFFIN OR PETROLATUM OR LANOLIN OR (GELATION HYDROCRA BON) OR (POLYETHYLENE GLYCOL) OR (OINTMENT BASE)) => s 14 and excipient# 10 L4 AND EXCIPIENT# => s 15 and (antiseptic# or surfactant# or preservative# or stabilzer# or alcohol# or ester# or oils) <----> SEARCH ENDED BY USER => s 15 and (antiseptic# or surfactant# or preservative# or stabilzer# or alcohol# or ester# or oil#) 5 FILES SEARCHED... 10 L5 AND (ANTISEPTIC# OR SURFACTANT# OR PRESERVATIVE# OR STABILZE R# OR ALCOHOL# OR ESTER# OR OIL#) => s 16 and (parahydroxybenzoate or chlorobutanol or (benzalkonium chloride)) 3 L6 AND (PARAHYDROXYBENZOATE OR CHLOROBUTANOL OR (BENZALKONIUM L7CHLORIDE)) => d 17 1-3 ibib abs ANSWER 1 OF 3 USPATFULL 2002:303977 USPATFULL ACCESSION NUMBER: TITLE: Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial INVENTOR(S): Tuse , Daniel, Menlo Park, CA, United States Mortelmans, Kristien, Los Altos Hills, CA, United States Hokama, Leslie A., Los Altos, CA, United States Selsted, Michael E., Irvine, CA, United States Chapoy, Larry L., Barrington, IL, United States Quinn, Michael H., Valparaiso, IN, United States PATENT ASSIGNEE(S): The Regents of the University of California, Oakland, CA, United States (U.S. corporation) NUMBER KIND DATE US 6482799 B1 20021119 PATENT INFORMATION: US 1999-318195 APPLICATION INFO.: 19990525 (9) DOCUMENT TYPE: Utility FILE SEGMENT: GRANTED PRIMARY EXAMINER: Jones, Dwyane C. ASSISTANT EXAMINER: Delacroix-Muirheid, C. Townsend and Townsned and Crew LLP LEGAL REPRESENTATIVE: NUMBER OF CLAIMS: 59 EXEMPLARY CLAIM: NUMBER OF DRAWINGS: 6 Drawing Figure(s); 6 Drawing Page(s) LINE COUNT: 3053 CAS INDEXING IS AVAILABLE FOR THIS PATENT. This invention provides a novel anti-microbial system suitable for formulation in a wide variety of ophthalmic solutions. In particular the composition comprises an antimicrobial peptide that is an

indolicidin and a buffer compatible with application to a mammalian eye, wherein the buffer is a Good's buffer or the buffer has a halide ion concentration less than 0.85 wt %. The compositions are useful for storing, cleaning, or disinfecting a contact lens. In particular the

compositions are self-preserving upon lengthy storage, effective in cleaning and sterilizing contact lenses upon exposure of the lens to the composition, do not require the need for physical or thermal treatment of the lens and enable the immediate application of the lens to the eye without the need for neutralization, deactivation or washing.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 2 OF 3 USPATFULL

ACCESSION NUMBER: 2001:212420 USPATFULL

TITLE: Immunostimulatory nucleic acids for inducing a Th2

immune response

INVENTOR(S): McCluskie, Michael J., Ottawa, Canada

Davis, Heather L., Ottawa, Canada

NUMBER DATE

PRIORITY INFORMATION: US 2000-177461P 20000120 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Helen Lockhart, c/o Wolf, Greenfield & Sacks, P.C.,

Federal Reserve Plaza, 600 Atlantic Avenue, Boston, MA,

02210-2211

NUMBER OF CLAIMS: 153 EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 14 Drawing Page(s)

LINE COUNT: 3831

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The invention relates to methods and products for inducing an immune response using immunostimulatory nucleic acids. In particular the immunostimulatory nucleic acids preferentially induce a Th2 immune response. The invention is useful for treating and preventing disorders associated with a Th1 immune response or for creating a Th2 environment for treating disorders that are sensitive to Th2 immune responses.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 3 OF 3 EUROPATFULL COPYRIGHT 2003 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1210947 EUROPATFULL EW 200223 FS OS TITLE: OPHTHALMIC OINTMENTS FOR TREATING INFECTIVE

OPHTHALMIC CINTMENTS FOR TREATING INFECT

EYE DISEASES.

AUGENSALBE ZUR BEHANDLUNG INFEKTIOESER AUGENKRANKHEITEN.

POMMADE OPHTALMIQUE POUR TRAITER LES MALADIES

INFECTIEUSES.

INVENTOR(S): KASAMA, Toshio, 35-11, Mejiro 4-chome, Toshima-ku, Tokyo

171-0031, JP;

NOTO, Mitsuru, 223-1, Ikuji, Kurobe-shi, Toyama

939-0066, JP;

OGURO, Susumu, 885, Dougenji, Tateyama-cho,

Nakaniikawa-gun, Toyama 930-0241, JP;

HANAZOME, Isao, 148, Shimoiino, Toyama-shi, Toyama

931-8443, JP;

TATEKAWA, Rena, 8-13, Sogawa 3-chome, Toyama-shi, Toyama

930-0083, JP

PATENT ASSIGNEE(S): Toa Pharmaceutical Co., Ltd., 26, Sangou, Toyama-shi,

Toyama 939-3548, JP

PATENT ASSIGNEE NO: 2698651

AGENT: Albrecht, Thomas, Dr. et al., Kraus & Weisert,

Thomas-Wimmer-Ring 15, 80539 Muenchen, DE

AGENT NUMBER: 83202

OTHER SOURCE: BEPA2002048 EP 1210947 A1 0008

SOURCE: Wila-EPZ-2002-H23-T1b

DOCUMENT TYPE: Patent

LANGUAGE: Anmeldung in Japanisch; Veroeffentlichung in Englisch;

Verfahren in Englisch

DESIGNATED STATES: R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R

GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE

PATENT INFO.PUB.TYPE: EPA1 EUROPAEISCHE PATENTANMELDUNG (Internationale

Anmeldung)

PATENT INFORMATION:

	PA'	TENT NO	KIND	DATE
	EP	1210947	A1	20020605
'OFFENLEGUNGS' DATE:				20020605
APPLICATION INFO.:	ΕP	2000-942352		20000628
PRIORITY APPLN. INFO.:	JP	1999-183345		19990629
RELATED DOC. INFO.:	WO	00-JP4226	00062	28 INTAKZ
	WO	0100226	01010	04 INTPNE

=> d his

(FILE 'HOME' ENTERED AT 09:15:48 ON 14 MAY 2003)

FILE 'CAPLUS, USPATFULL, JAPIO, EUROPATFULL, MEDLINE, BIOSIS, EMBASE'

ENTERED AT 09:16:13 ON 14 MAY 2003

L1 760 S VANCOMYCIN HYDROCHLORIDE

L2 65 S L1 AND OPHTHALM?

L3 11 S L2 AND KERATITIS

L4 11 S L3 AND (PARAFFIN OR PETROLATUM OR LANOLIN OR (GELATION HYDRO

L5 10 S L4 AND EXCIPIENT#

L6 10 S L5 AND (ANTISEPTIC# OR SURFACTANT# OR PRESERVATIVE# OR STABI

L7 3 S L6 AND (PARAHYDROXYBENZOATE OR CHLOROBUTANOL OR (BENZALKONIU

=> d 14 1-10 ibib abs

L4 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:12286 CAPLUS

DOCUMENT NUMBER: 134:61571

TITLE: Ophthalmic ointments for treating infective

eye diseases

INVENTOR(S):
Kasama, Toshio; Noto, Mitsuru; Oguro, Susumu;

Hanazome, Isao; Tatekawa, Rena

PATENT ASSIGNEE(S): Toa Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 15 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000226	A1	20010104	WO 2000-JP4226	20000628

W: US

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,

PT, SE

JP 2001010971 A2 20010116 JP 1999-183345 19990629 EP 1210947 A1 20020605 EP 2000-942352 20000628

AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY

PRIORITY APPLN. INFO.:

JP 1999-183345 A 19990629 WO 2000-JP4226 W 20000628

This invention relates to ophthalmic ointments for treating AB infective eye diseases which are particularly efficacious against infective eye diseases caused by methicillin resistant Staphylococcus aureus (MRSA) or methicillin resistant Staphylococcus epidermidis (MRSE) and contain as the active ingredient from 0.01 to 5.0 % of vancomycin hydrochloride. Compared with i.v. administration, topical administration of these ophthalmic ointments is accompanied with no problem of the occurrence of side effects

such as renal toxicity and thus enables the maintenance of a therapeutically effective concn. An ophthalmic ointment contained vancomycin.cntdot.HCl 1, paraffin oils 20, and white vaseline 79 g.

REFERENCE COUNT:

19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 2 OF 11 USPATFULL

ACCESSION NUMBER: 2002:314748 USPATFULL

TITLE: Pharmaceutical dipeptide compositions and methods of

use thereof: immunostimulants

INVENTOR(S): Kozhemyakin, Andrei L., St. Petersburg, RUSSIAN

FEDERATION

Sinackevich, Nickolai V., St. Petersburg, RUSSIAN

FEDERATION

Seryi, Sergey V., St. Petersburg, RUSSIAN FEDERATION Rakhilov, Alexei M., St. Petersburg, RUSSIAN FEDERATION

Morozov, Vyacheslav G., St. Petersburg, RUSSIAN

FEDERATION

Khavinson, Vladimir, St. Petersburg, RUSSIAN FEDERATION

Green, Lawrence R., Tacoma, WA, UNITED STATES

PATENT ASSIGNEE(S): Cytran, Inc., Kirkland, WA, UNITED STATES (non-U.S.

corporation)

NUMBER KIND DATE -----

PATENT INFORMATION: APPLICATION INFO.: RELATED APPLN. INFO.: US 2002177226 A1 20021128 US 2002-76707 A1 20020214 (10) Continuation of Ser. No. US 1997-977279, filed on 24

Nov 1997, PATENTED Continuation of Ser. No. US 1995-452411, filed on 26 May 1995, PATENTED Continuation of Ser. No. US 1994-278463, filed on 21 Jul 1994, ABANDONED Continuation-in-part of Ser. No. US 1995-401653, filed on 9 Mar 1995, ABANDONED Continuation-in-part of Ser. No. US 1994-257495, filed on 7 Jun 1994, ABANDONED Continuation-in-part of Ser. No. US 1995-370838, filed on 10 Jan 1995, ABANDONED

Continuation-in-part of Ser. No. US 1991-783518, filed on 28 Oct 1991, ABANDONED Continuation-in-part of Ser. No. US 1991-678129, filed on 1 Apr 1991, ABANDONED Continuation-in-part of Ser. No. US 1989-415283, filed on 30 Aug 1989, ABANDONED Continuation-in-part of Ser. No. US 1993-75842, filed on 10 Jun 1993, ABANDONED

NUMBER DATE

PRIORITY INFORMATION:

WO 1988-SU255 19881214

SU 1987-4352833 19871230

DOCUMENT TYPE: Utility FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO

CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834

NUMBER OF CLAIMS: EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 8271

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Methods of treatment of subjects for decreasing cell mediated

autoimmunity or humoral autoimmunity by administering an R'-Glu-Trp-R"

pharmaceutical preparation useful in subjects having autoimmune

diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 3 OF 11 USPATFULL

2002:303977 USPATFULL ACCESSION NUMBER:

TITLE: Self-preserving multipurpose ophthalmic

solutions incorporating a polypeptide antimicrobial

INVENTOR(S): Tuse , Daniel, Menlo Park, CA, United States

Mortelmans, Kristien, Los Altos Hills, CA, United

Hokama, Leslie A., Los Altos, CA, United States Selsted, Michael E., Irvine, CA, United States Chapoy, Larry L., Barrington, IL, United States Quinn, Michael H., Valparaiso, IN, United States

The Regents of the University of California, Oakland, PATENT ASSIGNEE(S):

CA, United States (U.S. corporation)

NUMBER KIND DATE _____

PATENT INFORMATION: US 6482799 B1 20021119
APPLICATION INFO.: US 1999-318195 19990525 19990525 (9)

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Jones, Dwyane C.
ASSISTANT EXAMINER: Delacroix-Muirheid, C.

LEGAL REPRESENTATIVE: Townsend and Townsned and Crew LLP

NUMBER OF CLAIMS: 59 EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 6 Drawing Figure(s); 6 Drawing Page(s)

LINE COUNT: 3053

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

This invention provides a novel anti-microbial system suitable for formulation in a wide variety of ophthalmic solutions. In particular the composition comprises an antimicrobial peptide that is an indolicidin and a buffer compatible with application to a mammalian eye, wherein the buffer is a Good's buffer or the buffer has a halide ion concentration less than 0.85 wt %. The compositions are useful for storing, cleaning, or disinfecting a contact lens. In particular the compositions are self-preserving upon lengthy storage, effective in cleaning and sterilizing contact lenses upon exposure of the lens to the composition, do not require the need for physical or thermal treatment of the lens and enable the immediate application of the lens to the eye without the need for neutralization, deactivation or washing.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 4 OF 11 USPATFULL

ACCESSION NUMBER: 2002:75189 USPATFULL

TITLE: Method of treating complications in immunodepressed

states resulting from HIV infection

INVENTOR(S): Kozhemyakin, Andrei L., St. Petersburg, RUSSIAN

FEDERATION

Sinackevich, Nickolai V., St. Petersburg, RUSSIAN

FEDERATION

Seryi, Sergey V., St. Petersburg, RUSSIAN FEDERATION Rakhilov, Alexei M., St. Petersburg, RUSSIAN FEDERATION

Morozov, Vyacheslav G., St. Petersburg, RUSSIAN

FEDERATION

Khavinson, Vladimir Kh., St. Petersburg, RUSSIAN

FEDERATION

PATENT ASSIGNEE(S): Cytran, Inc., Kirkland, WA, United States (U.S.

corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 6368788 B1 20020409 APPLICATION INFO.: US 1997-977279 19971124 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-452411, filed on 26

May 1995, now patented, Pat. No. US 5728680

Continuation-in-part of Ser. No. US 1994-278463, filed on 21 Jul 1994, now abandoned Continuation-in-part of Ser. No. US 1994-257495, filed on 7 Jun 1994, now abandoned Continuation of Ser. No. US 1991-783518,

filed on 28 Oct 1991, now abandoned

Continuation-in-part of Ser. No. US 1991-678129, filed

on 1 Apr 1991, now abandoned

NUMBER DATE

PRIORITY INFORMATION: SU 1987-4352833 19871230

DOCUMENT TYPE: Utility FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Park, Hankyel

LEGAL REPRESENTATIVE: Townsend and Townsend and Crew LLP

NUMBER OF CLAIMS: 14 EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 16 Drawing Figure(s); 8 Drawing Page(s)

LINE COUNT: 7640

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of treatment of subjects for decreasing cell mediated

autoimmunity or humoral autoimmunity by administering an R'-Glu-Trp-R"

pharmaceutical preparation useful in subjects having autoimmune

diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 11 USPATFULL

ACCESSION NUMBER: 2001:212420 USPATFULL

TITLE: Immunostimulatory nucleic acids for inducing a Th2

immune response

INVENTOR(S): McCluskie, Michael J., Ottawa, Canada

Davis, Heather L., Ottawa, Canada

NUMBER DATE

20000120 (60) PRIORITY INFORMATION: US 2000-177461P

DOCUMENT TYPE: Utility APPLICATION FILE SEGMENT:

LEGAL REPRESENTATIVE: Helen Lockhart, c/o Wolf, Greenfield & Sacks, P.C.,

Federal Reserve Plaza, 600 Atlantic Avenue, Boston, MA,

02210-2211

NUMBER OF CLAIMS: 153 EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 14 Drawing Page(s)

LINE COUNT: 3831

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The invention relates to methods and products for inducing an immune response using immunostimulatory nucleic acids. In particular the immunostimulatory nucleic acids preferentially induce a Th2 immune response. The invention is useful for treating and preventing disorders associated with a Th1 immune response or for creating a Th2 environment for treating disorders that are sensitive to Th2 immune responses.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 6 OF 11 USPATFULL

2001:131342 USPATFULL ACCESSION NUMBER:

TITLE: Conjugates of dithiocarbamate disulfides with

pharmacologically active agents and uses therefor

INVENTOR(S): Lai, Ching-San, Encinitas, CA, United States

Vassilev, Vassil P., San Diego, CA, United States

Wang, Tingmin, San Marcos, CA, United States

PATENT ASSIGNEE(S):

Medinox, Inc., San Diego, CA, United States (U.S.

corporation)

NUMBER KIND DATE

US 6274627 B1 20010814 US 1999-416619 19991012 (9) PATENT INFORMATION:
APPLICATION INFO.: APPLICATION INFO.:

DOCUMENT TYPE: Utility FILE SEGMENT: GRANTED

FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Weddington, Kevin E.

LEGAL REPRESENTATIVE: Reiter, Stephen E. Foley & Lardner

NUMBER OF CLAIMS: EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 4 Drawing Figure(s); 5 Drawing Page(s)

LINE COUNT: 2173

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

In accordance with the present invention, there are provided conjugates of physiologically compatible free radical scavengers (e.g., dithiocarbamate disulfides (DD)) and pharmacologically active agents (e.g., NSAIDS). Invention conjugates provide a new class of pharmacologically active agents (e.g., anti-inflammatory agents) which cause a much lower incidence of side-effects due to the protective effects imparted by modifying the pharmacologically active agents as described herein. In addition, invention conjugates are more effective than unmodified pharmacologically active agents because cells and tissues contacted by the pharmacologically active agent(s) are protected from the potentially damaging effects of free radical overproduction induced thereby as a result of the co-production of free radical scavenger (e.g., dithiocarbamate), in addition to free pharmacologically active agent, when invention conjugate is cleaved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 7 OF 11 USPATFULL

ACCESSION NUMBER: 1998:115714 USPATFULL

TITLE: Pharmaceutical dipeptide compositions and methods of

use thereof: immunodepressants

INVENTOR(S): Khavinson, Vladimir Kh., St. Petersburg, Russian

Federation

Morozov, Vyacheslav G., St. Petersburg, Russian

Federation

Cytran, Inc., Kirkland, WA, United States (U.S. PATENT ASSIGNEE(S):

corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 5811399 19980922 US 4509048 19950526 APPLICATION INFO.: 19950526 (8)

Continuation-in-part of Ser. No. 278463, filed on 21 RELATED APPLN. INFO.:

Jul 1994, now abandoned And Ser. No. 337341, filed on 10 Nov 1994, now patented, Pat. No. 5538951 which is a continuation-in-part of Ser. No. 257495, filed on 7 Jun 1994, now abandoned which is a continuation of Ser. No. 783518, filed on 28 Oct 1991, now abandoned which is a continuation-in-part of Ser. No.

filed on 1 Apr 1991, now abandoned which is a

continuation-in-part of Ser. No. 415283, filed on 30

Aug 1989, now abandoned

DOCUMENT TYPE: Utility FILE SEGMENT: Granted

PRIMARY EXAMINER: Tsang, Cecilia J. Harle, Jennifer ASSISTANT EXAMINER:

NUMBER OF CLAIMS: 12 EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 14 Drawing Figure(s); 7 Drawing Page(s)

LINE COUNT: 8863

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Methods of treatment of subjects for decreasing cell mediated

autoimmunity or humoral autoimmunity by administering an R'-Glu-Trp-R" pharmaceutical preparation useful in subjects having autoimmune

diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 8 OF 11 USPATFULL

ACCESSION NUMBER: 1998:111911 USPATFULL

TITLE: Method for treatment of purulent inflammatory diseases

INVENTOR(S): Morozov, Vyacheslav G., St. Petersburg, Russian

Federation

Khavinson, Vladimir Kh., St. Petersburg, Russian

Federation

Cytoven J.V., Kirkland, WA, United States (U.S. PATENT ASSIGNEE(S):

corporation)

NUMBER KIND DATE -**---**-----------PATENT INFORMATION: US 5807830 19980915

19950526 (8) US 1995-452061 APPLICATION INFO.:

Continuation-in-part of Ser. No. US 1994-337341, filed RELATED APPLN. INFO.: on 10 Nov 1994, now patented, Pat. No. US 5538951 And a continuation-in-part of Ser. No. US 1994-278463, filed

on 21 Jul 1994, now abandoned which is a

continuation-in-part of Ser. No. US 1994-257495, filed on 7 Jun 1994, now abandoned which is a continuation of Ser. No. US 1991-783518, filed on 28 Oct 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-678129, filed on 1 Apr 1991, now abandoned

which is a continuation-in-part of Ser. No. US 1989-415283, filed on 30 Aug 1989, now abandoned

DATE NUMBER -----

PRIORITY INFORMATION: SU 1987-4352833 19871230

DOCUMENT TYPE: Utility FILE SEGMENT: Granted

PRIMARY EXAMINER: Jones, W. Gary ASSISTANT EXAMINER: Fredman, Jeffrey

NUMBER OF CLAIMS: 11 EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 16 Drawing Figure(s); 8 Drawing Page(s)

LINE COUNT: 8879

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

This invention provides methods of treating purulent inflammatory diseases by administering L-Glu-L-Trp or a salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 9 OF 11 USPATFULL

ACCESSION NUMBER: 1998:72601 USPATFULL

Pharmaceutical dipeptide compositions and methods of TITLE:

use thereof: systemic toxicity

Morozov, Vyacheslav G., St. Petersburg, Russian INVENTOR(S):

Federation

Khavinson, Vladimir Kh., St. Petersburg, Russian

Federation

PATENT ASSIGNEE(S): Cytran, Inc., Kirkland, WA, United States (U.S.

corporation)

NUMBER KIND DATE _________ US 5770576 PATENT INFORMATION: 19980623 US 5770576 19980623 US 1995-452077 19950526 (8)

APPLICATION INFO.: RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-337341, filed on 10

Nov 1994, now patented, Pat. No. US 5538951 which is a division of Ser. No. US 1989-415283, filed on 30 Aug 1989 And a continuation-in-part of Ser. No. US

1994-278463, filed on 21 Jul 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-257495,

filed on 7 Jun 1994, now abandoned which is a

continuation of Ser. No. US 1991-783518, filed on 28 Oct 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-678129, filed on 1 Apr 1991, now abandoned which is a continuation-in-part of Ser. No. US 1989-415283, filed on 30 Aug 1989, now abandoned

DOCUMENT TYPE: Utility FILE SEGMENT: Granted

Robinson, Douglas W. PRIMARY EXAMINER:

ASSISTANT EXAMINER: Harle, Jennifer NUMBER OF CLAIMS: 13 EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 14 Drawing Figure(s); 7 Drawing Page(s)

LINE COUNT: 8823

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Methods of treatment of subjects with systemic toxicity by administering an R'-Glu-Trp-R" pharmaceutical preparation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

T.4 ANSWER 10 OF 11 USPATFULL ACCESSION NUMBER: 1998:28061 USPATFULL

TITLE: Methods for normalizing numbers of lymphocytes

INVENTOR(S): Morozov, Vyacheslav G., St. Petersburg, Russian

Federation

Khavinson, Vladimir Kh., St. Petersburg, Russian

Federation

PATENT ASSIGNEE(S): Cytoven J.V., Kirkland, WA, United States (U.S.

corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 5728680 19980317 APPLICATION INFO.: US 1995-452411 19950526 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-337341, filed

on 10 Nov 1994, now patented, Pat. No. US 5538951 And a continuation-in-part of Ser. No. US 1994-278463, filed

on 21 Jul 1994, now abandoned which is a

continuation-in-part of Ser. No. US 1994-257495, filed on 7 Jun 1994, now abandoned which is a continuation of Ser. No. US 1991-783518, filed on 28 Oct 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-678129, filed on 1 Apr 1991, now abandoned

which is a continuation-in-part of Ser. No. US 1989-415283, filed on 30 Aug 1989, now abandoned

NUMBER DATE

PRIORITY INFORMATION: SU 1987-4352833 19871230

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Feisee, Lila
ASSISTANT EXAMINER: Ungar, Susan

NUMBER OF CLAIMS: 12 EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 16 Drawing Figure(s); 8 Drawing Page(s)

LINE COUNT: 8309

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides methods for normalizing the numbers of lymphocytes in animals by administering the dipeptide L-Glu-L-Trp.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 1 OF 18 USPATFULL

ACCESSION NUMBER: 2003:13338 USPATFULL

TITLE: Methods of preventing and treating microbial infections

INVENTOR(S): Baker, Jr., James R., Ann Arbor, MI, United States

> Hamouda, Tarek, Ypsilanti, MI, United States Shih, Amy, Ann Arbor, MI, United States Myc, Andrzej, Ann Arbor, MI, United States

Regents of the University of Michigan, Ann Arbor, MI, PATENT ASSIGNEE(S):

United States (U.S. corporation)

NUMBER KIND

PATENT INFORMATION: US 6506803 B1 20030114 APPLICATION INFO.: US 2000-561111 20000428 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-474866, filed

on 30 Dec 1999

NUMBER DATE

PRIORITY INFORMATION: US 1999-131638P 19990428 (60)

DOCUMENT TYPE: Utility FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Page, Thurman K. ASSISTANT EXAMINER: Fubara, Blessing PRIMARY EXAMINER: LEGAL REPRESENTATIVE: Medlen & Carroll, LLP

NUMBER OF CLAIMS: 35 EXEMPLARY CLAIM:

38 Drawing Figure(s); 35 Drawing Page(s) NUMBER OF DRAWINGS:

LINE COUNT: 3200

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The present invention provides methods and compositions for inactivating

bacteria including bacterial spores using an oil-in-water

emulsion are provided. The oil-in-water emulsion

comprises an oil, a surfactant and an organic phosphate-based solvent. These methods can be used to inactivate a wide variety of microorganisms including bacteria, bacterial spores, fungi, fungal spores and enveloped viruses.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 2 OF 18 USPATFULL

ACCESSION NUMBER: 2002:332754 USPATFULL

Method for treating multiple sclerosis TITLE: INVENTOR(S): Hunter, William L., Vancouver, CANADA

PATENT ASSIGNEE(S): Angiotech Pharmaceuticals, Inc., Vancouver, CANADA

(non-U.S. corporation)

NUMBER KIND DATE -----US 6495579 B1 20021217 US 1998-88546 19980601 PATENT INFORMATION:

APPLICATION INFO.: 19980601 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-980549, filed

on 1 Dec 1997

NUMBER DATE

PRIORITY INFORMATION: US 1997-63087P 19971024 (60) US 1996-32215P 19961202 (60)

DOCUMENT TYPE: Utility

GRANTED FILE SEGMENT: PRIMARY EXAMINER: Geist, Gary ASSISTANT EXAMINER: Crane, L. E.

LEGAL REPRESENTATIVE: Seed Intellectual Property Law Group PLLC

NUMBER OF CLAIMS: 29 EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 167 Drawing Figure(s); 107 Drawing Page(s)

LINE COUNT: 8213

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Methods and compositions for treating or preventing inflammatory diseases such as psoriasis or multiple sclerosis are provided, comprising the step of delivering to the site of inflammation an anti-microtubule agent, or analogue or derivative thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 3 OF 18 USPATFULL

ACCESSION NUMBER: 2002:323211 USPATFULL

Compositions and methods for treating or preventing TITLE:

inflammatory diseases

INVENTOR(S): Hunter, William L., Vancouver, CANADA

PATENT ASSIGNEE(S): Angiotech Pharmaceuticals, Inc., Vancouver, CANADA

(non-U.S. corporation)

NUMBER KIND DATE US 2002183380 A1 20021205 US 2002-67467 A1 20020205 (10) PATENT INFORMATION:

APPLICATION INFO.:

Continuation of Ser. No. US 1999-368463, filed on 4 Aug RELATED APPLN. INFO.: 1999, ABANDONED Division of Ser. No. US 1998-88546,

filed on 1 Jun 1998, PENDING Continuation-in-part of Ser. No. US 1997-980549, filed on 1 Dec 1997, PENDING

NUMBER DATE -----

PRIORITY INFORMATION: US 1996-32215P 19961202 (60) US 1997-63087P 19971024 (60)

DOCUMENT TYPE: Utility FILE SEGMENT: APPLICATION

SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH LEGAL REPRESENTATIVE:

AVE, SUITE 6300, SEATTLE, WA, 98104-7092

NUMBER OF CLAIMS: 16 EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 107 Drawing Page(s)

LINE COUNT: 8178

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Methods and compositions for treating or preventing inflammatory diseases such as psoriasis or multiple sclerosis are provided, comprising the step of delivering to the site of inflammation an

anti-microtubule agent, or analogue or derivative thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 4 OF 18 USPATFULL

ACCESSION NUMBER: 2002:322559 USPATFULL

TITLE: AN IMPROVED METHOD FOR THE PRODUCTION AND PURIFICATION

OF ADENOVIRAL VECTORS

INVENTOR(S): Zhang, Shuyuan, Sugar Land, TX, UNITED STATES

Thwin, Capucine, Spring, TX, UNITED STATES Wu, Zheng, Sugar Land, TX, UNITED STATES

Cho, Toohyon, UNITED STATES

Gallagher, Shawn, Missouri City, TX, UNITED STATES

PATENT ASSIGNEE(S): Introgen Therapeutics, Inc. (U.S. corporation)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-203078, filed on 1 Dec

1998, PENDING Continuation-in-part of Ser. No. US 1997-975519, filed on 20 Nov 1997, GRANTED, Pat. No. US

6194191

NUMBER DATE

PRIORITY INFORMATION: US 1996-31329P 19961120 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Steven L. Highlander, FULBRIGHT & JAWORSKI L.L.P.,

Suite 2400, 600 Congress Avenue, Austin, TX, 78701

NUMBER OF CLAIMS: 4 EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 49 Drawing Page(s)

LINE COUNT: 6000

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The present invention addresses the need to improve the yields of viral vectors when grown in cell culture systems. In particular, it has been demonstrated that for adenovirus, the use of low-medium perfusion rates in an attached cell culture system provides for improved yields. In other embodiments, the inventors have shown that there is improved Ad-p53 production with cells grown in serum-free conditions, and in particular in serum-free suspension culture. Also important to the increase of yields is the use of detergent lysis. Combination of these aspects of the invention permits purification of virus by a single chromatography step that results in purified virus of the same quality as preparations from double CsCl banding using an ultracentrifuge.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 5 OF 18 USPATFULL

ACCESSION NUMBER: 2002:266351 USPATFULL

TITLE: Pharmaceutical compositions comprising desglymidodrine

as an active drug substance

INVENTOR(S): Sundgreen, Claus, Frederiksberg, DENMARK

Schultz, Ann Christina, Roskilde, DENMARK Schlyter, Jimmy Hirschsprung, Greve, DENMARK Mohr Olsen, Peder, Kirke Hyllinge, DENMARK

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Dike, Bronstein, Roberts & Cushman, Intellectual

Property Patent Practice, EDWARDS & ANGELL, LLP, 130

Water Street, Boston, MA, 02109

NUMBER OF CLAIMS: 75 EXEMPLARY CLAIM: 1 NUMBER OF DRAWINGS: 4 Drawing Page(s)

LINE COUNT: 3835

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Novel pharmaceutical compositions comprising desglymidodrine or a pharmaceutically acceptable salt thereof as an active drug substance. Desglymidodrine is the active metabolite of the prodrug midodrine. The pharmaceutical composition may be presented in a suitable dosage form for oral, parenteral, mucosal, nasal, sublingual, buccal, topical, vaginal, rectalor ocular etc. administration. A pharmaceutical composition of the invention may be in the form of an immediate and/or modified release composition or it may be designed to release the active drug substance, desglymidodrine, in a relatively fast manner in order to enable a relatively fast onset of the therapeutic effect. The compositions have a suitable shelf-life, i.e. the desglymidodrine contained in the composition is not subject to a significant degradation under storage conditions normally acceptable for pharmaceuticals.

Also disclosed is a method for treating animals such as, e.g. mammals and humans with a novel pharmaceutical composition comprising desglymidodrine.

Furthermore, is disclosed a novel use of desglymidodrine in the treatment of septic shock and to a method for treating mammals (e.g. humans) suffering from septic shock with a sufficient amount of desglymidodrine

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 6 OF 18 USPATFULL

ACCESSION NUMBER: 2002:242771 USPATFULL

TITLE:

PATENT INFORMATION: APPLICATION INFO.:

Biodegradable poly(beta-amino esters) and uses thereof

INVENTOR(S):

Langer, Robert S., Newton, MA, UNITED STATES
Lynn, David M., Somerville, MA, UNITED STATES
Putnam, David, Cambridge, MA, UNITED STATES
Amiji, Mansoor M., Attleboro, MA, UNITED STATES
Anderson, Daniel G., Framingham, MA, UNITED STATES

	NUMBER	KIND	DATE	
US	2002131951	A1	20020919	
US	2001-969431	A1	20011002	(9)

NUMBER DATE

PRIORITY INFORMATION: US 2001-305337P 20010713 (60) US 2000-239330P 20001010 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Choate, Hall & Stewart, Exchange Place, 53 State

Street, Boston, MA, 02109

NUMBER OF CLAIMS: 101 EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 9 Drawing Page(s)

LINE COUNT: 3093

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Poly(.beta.-amino esters) prepared from the conjugate addition of bis(secondary amines) or primary amines to a bis(acrylate ester) are described. Methods of preparing these polymers from commercially available starting materials are also provided. These tertiary amine-containing polymers are preferably biodegradable and biocompatible and may be used in a variety of drug delivery systems. Given the poly(amine) nature of these polymers, they are

particularly suited for the delivery of polynucleotides. Nanoparticles containing polymer/polynucleotide complexes have been prepared. The inventive polymers may also be used to encapsulate other agents to be delivered. They are particularly useful in delivering labile agents given their ability to buffer the pH of their surroundings.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 7 OF 18 USPATFULL

ACCESSION NUMBER: 2002:221072 USPATFULL

TITLE: Non-toxic antimicrobial compositions and methods of use

INVENTOR(S): Baker, James R., JR., Ann Arbor, MI, UNITED STATES

Hamouda, Tarek, Milan, MI, UNITED STATES Shih, Amy, Ann Arbor, MI, UNITED STATES Myc, Andrzej, Ann Arbor, MI, UNITED STATES

PATENT ASSIGNEE(S): The Regent of the University of Michigan, Ann Arbor,

MI, 48109 (U.S. corporation)

RELATED APPLN. INFO.: US 2001-965447 AI 20010927 (9)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-891086, filed

on 25 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2000-751059, filed on 29 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-561111, filed on 28 Apr 2000, PENDING Continuation-in-part of Ser. No. US 1999-474866, filed on 30 Dec 1999, ABANDONED

NUMBER DATE

PRIORITY INFORMATION: US 1999-131638P 19990428 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: MEDLEN & CARROLL, LLP, 101 HOWARD STREET, SUITE 350,

SAN FRANCISCO, CA, 94105

NUMBER OF CLAIMS: 18 EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 42 Drawing Page(s)

LINE COUNT: 4073

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compositions and methods for decreasing the infectivity, morbidity, and rate of mortality associated with a variety of pathogenic organisms and viruses. The present invention also relates to methods and compositions for decontaminating areas colonized or otherwise infected by pathogenic organisms and viruses. Moreover, the present invention relates to methods and compositions for decreasing the infectivity of pathogenic organisms in foodstuffs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 8 OF 18 USPATFULL

ACCESSION NUMBER: 2002:85621 USPATFULL

, TITLE: Non-toxic antimicrobial compositions and methods of use

INVENTOR(S): Baker, James R., JR., Ann Arbor, MI, UNITED STATES

Hamouda, Tarek, Ypsilanti, MI, UNITED STATES Shih, Amy, Ann Arbor, MI, UNITED STATES

Myc, Andrzej, Ann Arbor, MI, UNITED STATES
PATENT ASSIGNEE(S): The Regents of the University of Michigan, Ann Arbor,

MI (U.S. corporation)

NUMBER KIND DATE

_____ PATENT INFORMATION:

US 2002045667 A1 20020418 US 6559189 B2 20030506 US 2001-891086 A1 20010625 (9) APPLICATION INFO.:

Continuation-in-part of Ser. No. US 2000-751059, filed RELATED APPLN. INFO.:

> on 29 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-561111, filed on 28 Apr 2000, PENDING

Continuation-in-part of Ser. No. US 1999-474866, filed

on 30 Dec 1999, ABANDONED

NUMBER DATE ______

US 1999-131638P 19990428 (60) PRIORITY INFORMATION:

DOCUMENT TYPE: Utility FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: MEDLEN & CARROLL, LLP, Suite 2200, 220 Montgomery

Street, San Francisco, CA, 94104

NUMBER OF CLAIMS: 20 EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 42 Drawing Page(s)

LINE COUNT: 4174

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The present invention relates to compositions and methods for decreasing the infectivity, morbidity, and rate of mortality associated with a variety of pathogenic organisms and viruses. The present invention also relates to methods and compositions for decontaminating areas colonized or otherwise infected by pathogenic organisms and viruses. Moreover, the present invention relates to methods and compositions for decreasing the infectivity of pathogenic organisms in foodstuffs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 9 OF 18 USPATFULL

ACCESSION NUMBER: 2002:67266 USPATFULL

TITLE: COMPOSITIONS AND METHODS OF PACLITAXEL FOR PREVENTING

PSORIASIS

INVENTOR(S): HUNTER, WILLIAM L., VANCOUVER, CANADA

NUMBER KIND DATE -----US 2002037919 A1 20020328 US 6515016 B2 20030204 US 1997-980549 A1 19971201 (8) PATENT INFORMATION: APPLICATION INFO.:

NUMBER DATE

_____ PRIORITY INFORMATION:

US 1996-32215P 19961202 (60) US 1997-63087P 19971024 (60)

DOCUMENT TYPE: Utility APPLICATION FILE SEGMENT:

SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH LEGAL REPRESENTATIVE:

AVE, SUITE 6300, SEATTLE, WA, 98104-7092

NUMBER OF CLAIMS: EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 107 Drawing Page(s)

LINE COUNT: 6325

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The present invention provides methods for treating or preventing inflammatory diseases such as psoriasis or multiple sclerosis, comprising the step of delivering to the site of inflammation an anti-microtubule agent, or analogue or derivative thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 10 OF 18 USPATFULL

ACCESSION NUMBER: 2002:22462 USPATFULL

COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING TITLE:

INFLAMMATORY DISEASES

HUNTER, WILLIAM L., VANCOUVER, CANADA INVENTOR(S):

KIND DATE NUMBER ______ US 2002013298 A1 20020131 US 1999-368463 A1 19990804 PATENT INFORMATION:

APPLICATION INFO .: (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-88546, filed on 1 Jun 1998, PENDING Continuation-in-part of Ser. No. US

1997-980549, filed on 1 Dec 1997, PENDING

DATE NUMBER ______

US 1996-32215P 19961202 (60) US 1997-63087P 19971024 (60) PRIORITY INFORMATION:

DOCUMENT TYPE: Utility FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH

AVE, SUITE 6300, SEATTLE, WA, 98104-7092

45 NUMBER OF CLAIMS: EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 110 Drawing Page(s)

8318 LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Methods and compositions for treating or preventing inflammatory diseases such as psoriasis or multiple sclerosis are provided, comprising the step of delivering to the site of inflammation an anti-microtubule agent, or analogue or derivative thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 11 OF 18 USPATFULL L7

ACCESSION NUMBER: 1998:14497 USPATFULL

Solid fat nanoemulsions as vaccine delivery vehicles TITLE:

Anselem, Shimon, Rehovot, Israel INVENTOR(S):

Lowell, George H., Baltimore, MD, United States

Aviv, Haim, Rehovot, Israel

Friedman, Doron, Carmei Yosef, Israel

PATENT ASSIGNEE(S): Pharmos Corporation, New York, NY, United States (U.S.

corporation)

The United States of America as represented by the Secretary of the Army, Washington, DC, United States

(U.S. government)

	NUMBER KIND	DATE	
			•
PATENT INFORMATION:	US 5716637	19980210	
	WO 9426255	19941124	
APPLICATION INFO.:	US 1995-553350	19951116	(8)
	WO 1994-US5589	19940518	
		19951116	PCT 371 date
		19951116	PCT 102(e) date
RELATED APPLN. INFO.:	Continuation-in-part of	f Ser. No.	US 1993-63613, filed

inuation-in-part of Ser. No. US 1993-63613,

on 18 May 1993, now patented, Pat. No. US 5576016

° Utility DOCUMENT TYPE: FILE SEGMENT: Granted

PRIMARY EXAMINER: Kishore, Gollamudi S.

LEGAL REPRESENTATIVE: Pennie & Edmonds

NUMBER OF CLAIMS: 44 EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 13 Drawing Figure(s); 8 Drawing Page(s)

LINE COUNT: 1699

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The present invention provides pharmaceutical vaccine compositions that are nanoemulsions of particles having a lipid core which is in a solid or liquid crystalline phase at 25.degree. C., and which is surrounded by at least one phospholipid bilayer for the parenteral, oral, intranasal, rectal, vaginal or topical delivery of both hydrophilic and lipophilic immunogens. The particles have a mean diameter in the range of 10 to 250 nm and the immunogen is incorporated therein, either intrinsically prior to the homogenization process or extrinsically thereafter.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 12 OF 18 USPATFULL

ACCESSION NUMBER: 95:110218 USPATFULL

TITLE: Vaginal tissue moisturizing composition and

method

INVENTOR(S): Robinson, Joseph R., 41 Chequamegon Rd., Madison, WI,

United States 53719

PATENT INFORMATION: US 5474768 19951212
APPLICATION INFO.: US 1993-15683 19930209 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1991-732738, filed on 18

Jul 1991, now abandoned which is a continuation of Ser. No. US 1989-429755, filed on 31 Oct 1989, now abandoned

DOCUMENT TYPE: Utility FILE SEGMENT: Granted

PRIMARY EXAMINER: Kulkosky, Peter F.

NUMBER OF CLAIMS: 22 EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)

LINE COUNT: 1313

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A composition and method of moisturizing mammalian vaginal membranous tissue is disclosed. The composition utilized in this method includes water, a bioadhesive polymer as the moisturizing agent and a consistency-enhancing agent. The bioadhesive is a water-swellable, but water-insoluble, particulate, fibrous, cross-linked carboxy-functional polymer containing (a) a plurality of repeating units of which at least about 80 percent contain at least one carboxyl functionality, and (b) about 0.05 to about 1.5 percent cross-linking agent substantially free from polyalkenyl polyether. The consistency-enhancing agent is a watersoluble or -dispersible anionic or non-ionic polymer. The composition is contacted with the vaginal mucous membrane to be moisturized, and that contact is maintained for a time period sufficient to moisturize the contacted area.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 13 OF 18 EUROPATFULL COPYRIGHT 2003 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1092433 EUROPATFULL EW 200116 FS OS

TITLE: Compositions and methods for treating or preventing

inflammatory diseases.

Zubereitungen und Verfahren zur Behandlung oder Praevention von entzuendlichen Erkrankungen.

Compositions and methods for treating or preventing

inflammatory diseases.

INVENTOR(S): Hunter, William L., 135 Alexander Street, Vancouver,

B.C. V6A 1B8, CA

PATENT ASSIGNEE(S): Angiotech Pharmaceuticals, Inc., 6660 N.W. Marine Drive,

Vancouver, British Columbia V6T 1Z4, CA

PATENT ASSIGNEE NO: 1910123

AGENT: Gowshall, Jonathan Vallance, FORRESTER & BOEHMERT

Franz-Joseph-Strasse 38, 80801 Muenchen, DE

AGENT NUMBER: 6153

OTHER SOURCE: BEPA2001029 EP 1092433 A2 0184

SOURCE: Wila-EPZ-2001-H16-T1b

DOCUMENT TYPE: Patent

LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FI; R FR; R GB; R

GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE

PATENT INFO.PUB.TYPE: EPA2 EUROPAEISCHE PATENTANMELDUNG

PATENT INFORMATION:

L7 ANSWER 14 OF 18 EUROPATFULL COPYRIGHT 2003 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1090637 EUROPATFULL EW 200115 FS OS

TITLE: Compositions and methods for treating or preventing

inflammatory diseases.

Zubereitungen und Verfahren zur Behandlung oder Praevention von entzuendlichen Erkrankungen.

Compositions and methods for treating or preventing

inflammatory diseases.

INVENTOR(S): Hunter, William L., 135 Alxander Street, Vancouver B.C.

·V6A 1B8, CA

PATENT ASSIGNEE(S): Angiotech Pharmaceuticals, Inc., 6660 N.W. Marine Drive,

Vancouver, British Columbia V6T 1Z4, CA

PATENT ASSIGNEE NO: 1910123

AGENT: Gowshall, Jonathan Vallance, FORRESTER & BOEHMERT

Franz-Joseph-Strasse 38, 80801 Muenchen, DE

AGENT NUMBER: 61531

OTHER SOURCE: BEPA2001027 EP 1090637 A2 0184

SOURCE: Wila-EPZ-2001-H15-T1b

DOCUMENT TYPE: Patent

LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FI; R FR; R GB; R

GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE

PATENT INFO.PUB.TYPE: EPA2 EUROPAEISCHE PATENTANMELDUNG

PATENT INFORMATION:

PATENT NO KIND DATE
------EP 1090637 A2 20010411
'OFFENLEGUNGS' DATE: 20010411
APPLICATION INFO.: EP 2000-123537 19971202

PRIORITY APPLN. INFO.: US 1996-32215 19961202

US 1997-63087 19971024

RELATED DOC. INFO.: EP 941089 DIV

L7 ANSWER 15 OF 18 EUROPATFULL COPYRIGHT 2003 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1070502 EUROPATFULL EW 200104 FS OS

TITLE: Compositions and methods for treating or preventing

inflammatory diseases.

Zubereitungen und Verfahren zur Behandlung oder Praevention von entzuendlichen Erkrankungen.

Compositions and methods for treating or preventing

inflammatory diseases.

INVENTOR(S): The designation of the inventor has not yet been filed

PATENT ASSIGNEE(S): Angiotech Pharmaceuticals, Inc., 6660 N.W. Marine Drive,

Vancouver, British Columbia V6T 1Z4, CA

PATENT ASSIGNEE NO: 1910123

AGENT: Gowshall, Jonathan Vallance, FORRESTER & BOEHMERT

Franz-Joseph-Strasse 38, 80801 Muenchen, DE

AGENT NUMBER: 6153

OTHER SOURCE: BEPA2001007 EP 1070502 A2 0186

SOURCE: Wila-EPZ-2001-H04-T1b

DOCUMENT TYPE: Patent

LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch

DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FI; R FR; R GB; R

GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE

PATENT INFO.PUB.TYPE: EPA2 EUROPAEISCHE PATENTANMELDUNG

PATENT INFORMATION:

RELATED DOC. INFO.: EP 941089 DIV

L7 ANSWER 16 OF 18 EUROPATFULL COPYRIGHT 2003 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 941089 EUROPATFULL EW 200120 FS PS

TITLE: USE OF ANTI-MICROTUBULE AGENTS FOR TREATING OR

PREVENTING MULTIPLE SCLEROSIS.

VERWENDUNG VON ANTI-MIKROTUBULI MITTELN ZUR BEHANDLUNG

UND PROPHYLAXE DER MULTIPLEN SCLEROSE.

UTILISATION DES AGENTS ANTI-MICROTUBULES POUR TRAITER OU

PREVENIR LA SCLEROSE EN PLAQUES.

INVENTOR(S): HUNTER, William, L., 525 Penticton Street, Vancouver,

British Columbia V5K 3L7, CA

PATENT ASSIGNEE(S): Angiotech Pharmaceuticals, Inc., 6660 N.W. Marine Drive,

Vancouver, British Columbia V6T 1Z4, CA

PATENT ASSIGNEE NO: 1910123

AGENT: Gowshall, Jonathan Vallance et al., FORRESTER & BOEHMERT

Franz-Joseph-Strasse 38, 80801 Muenchen, DE

AGENT NUMBER: 61531

OTHER SOURCE: BEPB2001020 EP 0941089 B1 0169

SOURCE: Wila-EPS-2001-H20-T1

DOCUMENT TYPE: Patent

LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch

DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FI; R FR; R GB; R

GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE

PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale

Anmeldung)

PATENT INFORMATION:

PATENT NO KIND DATE

EP 941089 B1 20010516

'OFFENLEGUNGS' DATE: 19990915

APPLICATION INFO.: EP 1997-945697 19971202

PRIORITY APPLN. INFO.: US 1996-32215 19961202 US 1997-63087 19971024

RELATED DOC. INFO.: WO 97-CA910 971202 INTAKZ WO 9824427 980611 INTPNR

REFERENCE PAT. INFO.: EP 38567 A EP 262681 A EP 2717041 A

WO 94-12158 A WO 95-03795 A WO 95-35095 A US 5443458 A

US 5565439 A

REF. NON-PATENT-LIT.: DATABASE WPI Week 8619 Derwent Publications Ltd.,

London, GB; AN 86-123250 XP002062018 & JP61063613 A (MITSUI TOATSU CHEM. INC.), 1 April 1986 YA MIN WANG ET

AL.: "Preparation and characterization of

poly(lactic-co-glycolic acid) microspheres for targeted delivery of a novel anticancer agent, taxol" CHEM. PHARM. BULL., vol. 44, no. 10, 1996, pages 1935-1940,

XP000633466

L7 ANSWER 17 OF 18 EUROPATFULL COPYRIGHT 2003 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 431719 EUROPATFULL EW 199124 FS OS STA B

TITLE: Vaginal tissue moisturizing composition and

method.

Mittel zur Feuchthaltung vaginalen Gewebes

sowie Verfahren dazu.

Composition pour hydrater le tissu vaginal et

procede.

INVENTOR(S): Robinson, Joseph R., 41 Chequamegon Bay Madison,

Wisconsin 53719, US

PATENT ASSIGNEE(S): COLUMBIA LABORATORIES, INC., 16400 NW 2nd Avenue, Miami

Florida 33169, US

PATENT ASSIGNEE NO: 1185900

AGENT: Fisher, Adrian John et al, CARPMAELS & RANSFORD 43

Bloomsbury Square, London WC1A 2RA, GB

AGENT NUMBER: 52611

OTHER SOURCE: ESP1991042 EP 0431719 A1 910612

SOURCE: Wila-EPZ-1991-H24-T1

DOCUMENT TYPE: Patent

LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch

DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R

IT; R LI; R LU; R NL; R SE

PATENT INFO. PUB. TYPE: EPA1 EUROPAEISCHE PATENTANMELDUNG

PATENT INFORMATION:

PATENT NO KIND DATE

EP 431719 A1 19910612

'OFFENLEGUNGS' DATE: 19910612

APPLICATION INFO.: EP 1990-300340 19900111

PRIORITY APPLN. INFO.: US 1989-429755 19891031

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 431719 EUROPATFULL EW 199445 FS PS STA B

TITLE: Vaginal tissue moisturizing composition.
Mittel zur Feuchthaltung vaginalen Gewebes.

Composition pour hydrater le tissu vaginal.

INVENTOR(S): Robinson, Joseph R., 41 Chequamegon Bay Madison, Wisconsin 53719, US

PATENT ASSIGNEE(S): COLUMBIA LABORATORIES, INC., 16400 NW 2nd Avenue, Miami

Florida 33169, US

PATENT ASSIGNEE NO: 1185900

AGENT: Fisher, Adrian John et al, CARPMAELS & RANSFORD 43

Bloomsbury Square, London WC1A 2RA, GB

AGENT NUMBER: 52613

OTHER SOURCE: EPB1994078 EP 0431719 B1 941109

SOURCE: Wila-EPS-1994-H45-T1

DOCUMENT TYPE: Patent

LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R

IT; R LI; R LU; R NL; R SE

PATENT INFO. PUB. TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT

PATENT INFORMATION:

PRIORITY APPLN. INFO.: US 1989-429755 19891031
REFERENCE PAT. INFO.: WO 89-06964 A US 4615697 A

US 4863725 A

REF. NON-PATENT-LIT.: CHEMICAL ABSTRACTS, Vol.99, no. 14, October 1983, page

343, abstract no. 110774g

L7 ANSWER 18 OF 18 EUROPATFULL COPYRIGHT 2003 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 429156 EUROPATFULL EW 199122 FS OS STA B TITLE: Method of moisturizing tissue and composition.

Verfahren zur Feuchthaltung von Gewebe und Mittel dazu.

Procede d'hydratation de tissus et composition.

Throwwood (a)

INVENTOR(S): Robinson, Joseph R., 41 Chequamegon Bay, Madison, 53719

Wisconsin, US

PATENT ASSIGNEE(S): COLUMBIA LABORATORIES, INC., 16400 NW 2nd Avenue, Miami

Florida 33169, US

PATENT ASSIGNEE NO: 1185900

AGENT: Fisher, Adrian John et al, CARPMAELS & RANSFORD 43

Bloomsbury Square, London WC1A 2RA, GB

AGENT NUMBER: 52611

OTHER SOURCE: ESP1991039 EP 0429156 A1 910529

SOURCE: Wila-EPZ-1991-H22-T1

DOCUMENT TYPE: Patent

LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R

IT; R LI; R LU; R NL; R SE

PATENT INFO. PUB. TYPE: EPA1 EUROPAEISCHE PATENTANMELDUNG

PATENT INFORMATION:

PATENT NO KIND DATE

EP 429156 A1 19910529

'OFFENLEGUNGS' DATE: 19910529

APPLICATION INFO.: EP 1990-300327 19900111

PRIORITY APPLN. INFO.: US 1989-429770 19891031

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 429156 EUROPATFULL EW 199439 FS PS STA B

TITLE: Method of moisturizing tissue and composition.

Verfahren zur Feuchthaltung von Gewebe und Mittel dazu.

Procede d'hydratation de tissus et composition.

INVENTOR(S): Robinson, Joseph R., 41 Chequamegon Bay, Madison, 53719

Wisconsin, US

PATENT ASSIGNEE(S): COLUMBIA LABORATORIES, INC., 16400 NW 2nd Avenue, Miami

Florida 33169, US

PATENT ASSIGNEE NO: 1185900

AGENT: Fisher, Adrian John et al, CARPMAELS & RANSFORD 43

Bloomsbury Square, London WC1A 2RA, GB

AGENT NUMBER: 5261

OTHER SOURCE: EPB1994069 EP 0429156 B1 940928

SOURCE: Wila-EPS-1994-H39-T1

DOCUMENT TYPE: Patent

LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch

DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R

IT; R LI; R LU; R NL; R SE

PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT

PATENT INFORMATION:

APPLICATION INFO.: EP 1990-300327 19900111 PRIORITY APPLN. INFO.: US 1989-429770 19891031

REFERENCE PAT. INFO.: WO 89-06964 A US 4615697 A

US 4863725 A